Synairgen (SYNG)

London
152.70
+1.00(+0.66%)
  • Volume:
    1,163,689
  • Bid/Ask:
    145.00/159.00
  • Day's Range:
    149.00 - 156.30

SYNG Overview

Prev. Close
151.7
Day's Range
149-156.3
Revenue
-
Open
152.9
52 wk Range
74.8-199.96
EPS
-0.1
Volume
1,163,689
Market Cap
307.45M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,493,957
P/E Ratio
-
Beta
-7.56
1-Year Change
-20.05%
Shares Outstanding
201,341,825
Next Earnings Date
09 May 2022
What is your sentiment on Synairgen?
or
Market is currently closed. Voting is open during market hours.

Synairgen News

Synairgen Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyBuyBuy
Technical IndicatorsStrong SellSellStrong BuyBuySell
SummarySellNeutralStrong BuyBuyNeutral

Synairgen Company Profile

Synairgen Company Profile

Employees
18

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.

Read More
  • Like Omega Diagnostics, Synairgen is a yo-yo stock. Nonetheless, these pharmaceutical companies will deliver not only COVID drugs but medications/inhalers for many lung related conditions. If you do have positions then HOLD, you will be rewarded
    0
    • Thursday will be the day for infromation as to how company plans to rollout next year with irish subsiduary looks very very promsiing
      1
      • Write up in the guardian. Forecasted revenue of £582m & global approval early next year. Q4 is going to be explosive.
        1
        • Cheers Nathan, this could be what we have been waiting for, anyone who has shares in this and “other” COVID/respiratory delevoping medication companies should deliberate before selling out, its definate “HOLD”
          1
      • Poly RNS and H2 is news time. Time running out, so fomo
        1
        • What has initiated the sudden jump, i cannot find any news updates to reflect a 10++% increase?
          1
          • We are on the cusp, next week should bring some welcomed news
            2
            • When will this rocket?
              1
              • 300
                1
                • Short sellers forcing the price down, as usual 😤😤
                  1
                  • When will this rise to the moon?
                    0
                    • why is this dropping so much after good news?
                      0
                      • Same thoughts Ahmed!
                        0
                    • Why sell? Company are and will continue to develop inhalers for Covid which no one has intimated it miraculously disappear. Other than the above , it is a company researching medications for all lung diseases which regretably costs lives
                      1
                      • I don't think that anyone is against this company making inhalers that help people. But the cause for the huge drop appears to be that by the time they get this inhaler is ready for distribution the pandemic will likely be over. Yes there will be other uses of course, and that's great. But reading the last press release the company said that they were even surprised at how few, I believe only 2 patients, in the placebo group were admitted to hospital and they pulled through. Which implies the study really didn't show much effectiveness, unless it was showing covid isn't that bad afterall. Had they used their heads and taken the inhaler where it's really needed in places like India at the moment and really put it through it paces and actually helped some people along the way then I might have left my money invested in synairgen. But the truth is they are aiming for profit, so you can't expect people to hold out...if they try to help those poor folk in India, then I'd be back in.
                        1
                    • And for those that consider giving the “thumbs down” need to wake up and smell the coffee, this company and others developing such medicines will save lives...or have you shorted the stock and its going against your position....Just to reiterate, we need these companies and their scientists so please back them
                      3
                      • No reason for this to falter, but again the inhaler needs to work for both COVID and other lung conditions. If thats proved, then i agree with Andrew & Ahmed....👍👍
                        2
                        • 500 soon
                          1
                          • anyone think this is worth buying now?
                            2
                            • When is this stock going to the moon?
                              2
                              • On occasions you have to go with your gut instinct and not follow what the media/journals say, that includes the Telegraph. If this inhaler medically works to save patients, not just now due to COVID, but future respiratory issues, Synairgen will have big support, financially backed and in the trading market
                                0
                                • Telegragh says SELL! https://www.telegraph.co.uk/investing/shares/questor-speculative-bet-covid-treatment-has-made-us-92pc-bank/?WT.mc_id=tmgliveapp_iosshare_Awk0Ry86MM71
                                  9
                                  • No logical reason for this to dip, COVID patients enrolled for next phase of testing. Company has a proven solid performance, just need to hold your nerves and wait
                                    0
                                    • This is gonna tank once GSK release their covid therapeutic. And AZ also coming with a therapeutic. Both resistant to all strains of covid and are single injections.
                                      15
                                      • Highly unlikely but with the new virus escape being discussed by the scientific community today, this may have huge issues for Mabs therapeutics coming along. The virus escape shouldn't impact sng001. You might find your own stock coming under pressure.
                                        0
                                      • The new drugs on the way are specifically designed to get all strains of covid. Do some research.
                                        4
                                      • Would you really trust gsk after their history with vaccines? https://www.buzzfeed.com/shaunlintern/these-nhs-staff-were-told-the-swine-flu-vaccine-was-safe
                                        0
                                    • This is must stock to add to the portfolio, inhaled nebuliser for Covid relief will not just help keep patients off ventilators but ease the pressures on our NHS, big buyer of this
                                      1
                                      • Greatest Jump....21% Higher
                                        0
                                        • This is only going to go up massive potential, ive been in it since summer and way down on overall position however come next year around april -may time should be huge returns.
                                          0
                                          • Moving up
                                            0
                                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.